198 related articles for article (PubMed ID: 29126161)
1. Early participant-reported symptoms as predictors of adherence to anastrozole in the International Breast Cancer Intervention Studies II.
Sestak I; Smith SG; Howell A; Forbes JF; Cuzick J
Ann Oncol; 2018 Feb; 29(2):504-509. PubMed ID: 29126161
[TBL] [Abstract][Full Text] [Related]
2. Anastrozole versus tamoxifen for the prevention of locoregional and contralateral breast cancer in postmenopausal women with locally excised ductal carcinoma in situ (IBIS-II DCIS): a double-blind, randomised controlled trial.
Forbes JF; Sestak I; Howell A; Bonanni B; Bundred N; Levy C; von Minckwitz G; Eiermann W; Neven P; Stierer M; Holcombe C; Coleman RE; Jones L; Ellis I; Cuzick J;
Lancet; 2016 Feb; 387(10021):866-73. PubMed ID: 26686313
[TBL] [Abstract][Full Text] [Related]
3. Participant-Reported Symptoms and Their Effect on Long-Term Adherence in the International Breast Cancer Intervention Study I (IBIS I).
Smith SG; Sestak I; Howell A; Forbes J; Cuzick J
J Clin Oncol; 2017 Aug; 35(23):2666-2673. PubMed ID: 28661758
[TBL] [Abstract][Full Text] [Related]
4. Weight change associated with anastrozole and tamoxifen treatment in postmenopausal women with or at high risk of developing breast cancer.
Sestak I; Harvie M; Howell A; Forbes JF; Dowsett M; Cuzick J
Breast Cancer Res Treat; 2012 Jul; 134(2):727-34. PubMed ID: 22588672
[TBL] [Abstract][Full Text] [Related]
5. Use of anastrozole for breast cancer prevention (IBIS-II): long-term results of a randomised controlled trial.
Cuzick J; Sestak I; Forbes JF; Dowsett M; Cawthorn S; Mansel RE; Loibl S; Bonanni B; Evans DG; Howell A;
Lancet; 2020 Jan; 395(10218):117-122. PubMed ID: 31839281
[TBL] [Abstract][Full Text] [Related]
6. Anastrozole for prevention of breast cancer in high-risk postmenopausal women (IBIS-II): an international, double-blind, randomised placebo-controlled trial.
Cuzick J; Sestak I; Forbes JF; Dowsett M; Knox J; Cawthorn S; Saunders C; Roche N; Mansel RE; von Minckwitz G; Bonanni B; Palva T; Howell A;
Lancet; 2014 Mar; 383(9922):1041-8. PubMed ID: 24333009
[TBL] [Abstract][Full Text] [Related]
7. Anastrozole versus tamoxifen in postmenopausal women with ductal carcinoma in situ undergoing lumpectomy plus radiotherapy (NSABP B-35): a randomised, double-blind, phase 3 clinical trial.
Margolese RG; Cecchini RS; Julian TB; Ganz PA; Costantino JP; Vallow LA; Albain KS; Whitworth PW; Cianfrocca ME; Brufsky AM; Gross HM; Soori GS; Hopkins JO; Fehrenbacher L; Sturtz K; Wozniak TF; Seay TE; Mamounas EP; Wolmark N
Lancet; 2016 Feb; 387(10021):849-56. PubMed ID: 26686957
[TBL] [Abstract][Full Text] [Related]
8. Effects of anastrozole on cognitive performance in postmenopausal women: a randomised, double-blind chemoprevention trial (IBIS II).
Jenkins VA; Ambroisine LM; Atkins L; Cuzick J; Howell A; Fallowfield LJ
Lancet Oncol; 2008 Oct; 9(10):953-61. PubMed ID: 18768369
[TBL] [Abstract][Full Text] [Related]
9. Improving informed consent: pilot of a decision aid for women invited to participate in a breast cancer prevention trial (IBIS-II DCIS).
Juraskova I; Butow P; Lopez A; Seccombe M; Coates A; Boyle F; McCarthy N; Reaby L; Forbes JF
Health Expect; 2008 Sep; 11(3):252-62. PubMed ID: 18816321
[TBL] [Abstract][Full Text] [Related]
10. The impact of body mass index on breast cancer incidence among women at increased risk: an observational study from the International Breast Intervention Studies.
Smith SG; Sestak I; Morris MA; Harvie M; Howell A; Forbes J; Cuzick J
Breast Cancer Res Treat; 2021 Jul; 188(1):215-223. PubMed ID: 33656637
[TBL] [Abstract][Full Text] [Related]
11. Risk factors for joint symptoms in patients enrolled in the ATAC trial: a retrospective, exploratory analysis.
Sestak I; Cuzick J; Sapunar F; Eastell R; Forbes JF; Bianco AR; Buzdar AU;
Lancet Oncol; 2008 Sep; 9(9):866-72. PubMed ID: 18703382
[TBL] [Abstract][Full Text] [Related]
12. Evolving uses of hormonal agents for breast cancer therapy.
Cummings FJ
Clin Ther; 2002; 24 Suppl C():C3-25. PubMed ID: 12117074
[TBL] [Abstract][Full Text] [Related]
13. Patient-reported outcomes with anastrozole versus tamoxifen for postmenopausal patients with ductal carcinoma in situ treated with lumpectomy plus radiotherapy (NSABP B-35): a randomised, double-blind, phase 3 clinical trial.
Ganz PA; Cecchini RS; Julian TB; Margolese RG; Costantino JP; Vallow LA; Albain KS; Whitworth PW; Cianfrocca ME; Brufsky AM; Gross HM; Soori GS; Hopkins JO; Fehrenbacher L; Sturtz K; Wozniak TF; Seay TE; Mamounas EP; Wolmark N
Lancet; 2016 Feb; 387(10021):857-65. PubMed ID: 26686960
[TBL] [Abstract][Full Text] [Related]
14. Symptoms and QOL as Predictors of Chemoprevention Adherence in NRG Oncology/NSABP Trial P-1.
Land SR; Walcott FL; Liu Q; Wickerham DL; Costantino JP; Ganz PA
J Natl Cancer Inst; 2016 Apr; 108(4):. PubMed ID: 26615179
[TBL] [Abstract][Full Text] [Related]
15. Anastrozole-Induced Carpal Tunnel Syndrome: Results From the International Breast Cancer Intervention Study II Prevention Trial.
Spagnolo F; Sestak I; Howell A; Forbes JF; Cuzick J
J Clin Oncol; 2016 Jan; 34(2):139-43. PubMed ID: 26598748
[TBL] [Abstract][Full Text] [Related]
16. Effect of baseline oestradiol serum concentration on the efficacy of anastrozole for preventing breast cancer in postmenopausal women at high risk: a case-control study of the IBIS-II prevention trial.
Cuzick J; Chu K; Keevil B; Brentnall AR; Howell A; Zdenkowski N; Bonanni B; Loibl S; Holli K; Evans DG; Cummings S; Dowsett M
Lancet Oncol; 2024 Jan; 25(1):108-116. PubMed ID: 38070530
[TBL] [Abstract][Full Text] [Related]
17. Estimating the magnitude of clinical benefit of systemic therapy in patients with DCIS or pre-invasive disease of the breast.
Lazzeroni M; Puntoni M; Provinciali N; Webber TB; Briata IM; D'Amico M; Giuliano S; Siri G; Cagnacci S; DeCensi A
Breast; 2019 Nov; 48 Suppl 1():S39-S43. PubMed ID: 31839158
[TBL] [Abstract][Full Text] [Related]
18. Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. Arimidex Study Group.
Nabholtz JM; Buzdar A; Pollak M; Harwin W; Burton G; Mangalik A; Steinberg M; Webster A; von Euler M
J Clin Oncol; 2000 Nov; 18(22):3758-67. PubMed ID: 11078488
[TBL] [Abstract][Full Text] [Related]
19. Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability study.
Bonneterre J; Thürlimann B; Robertson JF; Krzakowski M; Mauriac L; Koralewski P; Vergote I; Webster A; Steinberg M; von Euler M
J Clin Oncol; 2000 Nov; 18(22):3748-57. PubMed ID: 11078487
[TBL] [Abstract][Full Text] [Related]
20. Anastrozole ('Arimidex') versus tamoxifen as first-line therapy in postmenopausal women with advanced breast cancer: results of the double-blind cross-over SAKK trial 21/95--a sub-study of the TARGET (Tamoxifen or 'Arimidex' Randomized Group Efficacy and Tolerability) trial.
Thürlimann B; Hess D; Köberle D; Senn I; Ballabeni P; Pagani O; Perey L; Aebi S; Rochlitz C; Goldhirsch A
Breast Cancer Res Treat; 2004 Jun; 85(3):247-54. PubMed ID: 15111763
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
